For citations:
Filonenko DA, Ibragimova TM, Polshina NI, Belogurova AV, Khatkova EI, Arutiunian EA, Volkova EI, Zhukova LG. Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice. Meditsinskiy sovet = Medical Council. 2021;(20):75-82. (In Russ.) https://doi.org/10.21518/2079-701X-2021-20-75-82